Surge Laboratories is one of the most promising pharmaceutical companies from Pakistan which has successfully qualified for the ICHQ-7 compliance audit conducted by Rephine UK and now preparing to launch and market its Microencapsulated APIs in EU, Central & North American markets.

The company is already doing successful business in Asia, Middle East & North Africa, South America and has strategically collaborated with leading European trading and distribution companies for its Microencapsulated APIs and Excipients.

Surge has invested significantly in its state of the art cGMP compliant manufacturing facility which is fully equipped with latest technologies, most modern machinery and equipment to mitigate risk and produce high quality pharmaceutical branded generic formulations and value added Microencapsulated APIs. The facility has dedicated sections for Dry Powder Cephalosporin Injectables, Liquid Injectables & Microencapsulated APIs and Excipients.

Microencapsulation is the process by which small particles or droplets are surrounded by a coating to produce capsules for the purpose of shielding the API or excipient from the surrounding environment in the micrometer to millimeter range.

At Surge Microencapsulation of APIs and Excipients is carried out at all level; from laboratory scale to bulk scale on latest European equipment and following Microencapsulation operations are conducted with high precision.

— Taste Masking of Bitter APIs

— Enteric Coated Pellets & MUPS

— Moisture Protective Coating

— DC Coated Granules / Pellets

— Sustained/Modified Release Pellets

Thus, Surge is focusing to embrace latest pharmaceutical technologies to introduce innovative pharmaceutical products, microencapsulated/coated APIs and professional pharmaceutical services in the country to excel the pharmaceutical product compliance, improve the overall health standards and enhance the quality of life.

Copyright Business Recorder, 2020